Latest / Ageless Future / Navigating the Peptide Landscape: Quality, Regulation, and Informed Choices
Transcript
- 0:00Speaker 1: You're going to probably be bombarded every day. Someone's showing
- 0:04Speaker 1: you there's peptides all over the internet. Make sure you're
- 0:08Speaker 1: getting it through a five H three A license compounding pharmacy.
- 0:14Speaker 1: Those poor quality peptides can create potential harm. If you
- 0:19Speaker 1: actually look at the FDA Category two lists, there's nineteen
- 0:24Speaker 1: peptides that are currently under review. That includes your BPC
- 0:28Speaker 1: one five seven, CJC twelve ninety five. They're stating there's
- 0:32Speaker 1: insufficient safety and efficacy data. There's at least seven key
- 0:37Speaker 1: peptides that we've heard of that should be getting back
- 0:40Speaker 1: on the Category one list. We're going to be talking
- 0:44Speaker 1: about some of the truth behind peptides today. Welcome to
- 1:01Speaker 1: the Agels Future podcast. This is your host today, Kate Archibald,
- 1:05Speaker 1: and today we'll dive in on the truth behind research
- 1:10Speaker 1: use only peptides. So I've been talked to a lot.
- 1:14Speaker 1: I have different friends that will come to me and
- 1:16Speaker 1: ask me about different peptides that they use, and and
- 1:21Speaker 1: and things, and so it's, uh, it's one of those
- 1:25Speaker 1: things that we have. It seems like there's more and
- 1:32Speaker 1: more noise in the peptide world just as as they
- 1:37Speaker 1: gain in popularity and so what I've noticed is just
- 1:43Speaker 1: this significant amount of different influencers, different groups and that
- 1:51Speaker 1: are promoting these, you know a lot of different peptides.
- 1:56Speaker 1: For we we refer to them as are you O
- 2:00Speaker 1: or research you so only And so I want to
- 2:04Speaker 1: kind of talk a little bit about what that means
- 2:07Speaker 1: and what you want to look out for on there.
- 2:11Speaker 1: So you know it's there, there's this huge explosion in
- 2:15Speaker 1: growth and peptides. They are super popular. You know, it's
- 2:18Speaker 1: really popular to to lose some weight, gain some muscle,
- 2:22Speaker 1: sleep better, better cognition. Like peptides have just been a
- 2:27Speaker 1: game changer when it comes to health and longevity and
- 2:31Speaker 1: and and so you know rightfully, so they are just
- 2:35Speaker 1: these these amazing molecules, short chain of amino acids that
- 2:42Speaker 1: can provide some really good boosts and results for for
- 2:45Speaker 1: our health. And so you know, there's what's what's happened though,
- 2:50Speaker 1: is the FDA has really taken this kind of like
- 2:54Speaker 1: back backstand and historically it was like hands off, we're
- 3:00Speaker 1: not really going to talk about them. And then in
- 3:03Speaker 1: twenty twenty one, and so that's where there was a
- 3:06Speaker 1: lot of kind of gray market as well as you
- 3:09Speaker 1: had a lot more access of really good pharmacies making
- 3:16Speaker 1: all the different peptides. But twenty twenty I don't even
- 3:21Speaker 1: recall the exact I think it was twenty one twenty
- 3:24Speaker 1: two they came out and or no, it was twenty four.
- 3:27Speaker 1: They came out and put some specific peptides on the
- 3:32Speaker 1: category two list, and so there's only a very select
- 3:36Speaker 1: few category one peptides and then the rest are kind
- 3:39Speaker 1: of like no one's supposed to bolt compound these. So
- 3:43Speaker 1: five oh three B pharmacies. So just to give you
- 3:46Speaker 1: guys a little bit of information on pharmacies, you have
- 3:49Speaker 1: five oh three B is in bravo. Those pharmacies are
- 3:53Speaker 1: able to kind of mass produce at large scale, large batches,
- 3:59Speaker 1: and they supply peptides to either clinics or they can
- 4:03Speaker 1: provide peptides to other pharmacies, like five O three A pharmacies.
- 4:09Speaker 1: Five O three A pharmacies are specific pitot A script
- 4:13Speaker 1: needs to be attached to it in order for it
- 4:16Speaker 1: to go out of that buondancy. And so there's they
- 4:20Speaker 1: are considered patient specific pharmacies, and so you know, and
- 4:26Speaker 1: then there's there's a bunch of different types of pharmacies
- 4:29Speaker 1: from there. Sterile non sterile all those other licenses that
- 4:32Speaker 1: go along with it. But ultimately, by the FDA coming
- 4:37Speaker 1: out and creating this, you know, this positioning, they really
- 4:43Speaker 1: kind of in these kind of like a gray market
- 4:48Speaker 1: not you know, for research use only peptides, which essentially
- 4:53Speaker 1: they're they're labeled as not for human consumption, and the
- 4:58Speaker 1: reason why they're labeled that is to to get around
- 5:00Speaker 1: a regulatory loophole. And you know, in the past, there's
- 5:05Speaker 1: you know, maybe maybe it's been. The belief now is
- 5:09Speaker 1: they're they're being so mass produced in huge quantities from
- 5:14Speaker 1: the research use only side of things, where it's it's
- 5:18Speaker 1: questionable how safe I actually are. In the past it
- 5:22Speaker 1: was like, oh, well, you know, maybe maybe it is okay,
- 5:27Speaker 1: but that's that's not not the case at all, and
- 5:29Speaker 1: so we we want to you know, provide some some
- 5:33Speaker 1: guidance there, some some of our own personal recommendations as
- 5:37Speaker 1: well as just make sure you guys are paying attention
- 5:40Speaker 1: to this, because there's different websites you can hop on
- 5:44Speaker 1: and you'll see, you know, really cheap costs for peptides.
- 5:48Speaker 1: But essentially we don't know exactly where they're coming from.
- 5:53Speaker 1: There's no physician or a pharmacist. That's actually like signing
- 5:58Speaker 1: off saying yes, I'm putting my life since online saying
- 6:01Speaker 1: this is a good, high quality product, versus you know,
- 6:05Speaker 1: someone white labeling a peptide violin saying like, hey, this
- 6:11Speaker 1: is a new peptide store. I have come grab some peptides.
- 6:14Speaker 1: I mean they're coming from mass manufacturers from China typically,
- 6:18Speaker 1: or you don't really know exactly what's in it. They
- 6:21Speaker 1: can put some cva's certificates of analysis alongside it. But
- 6:27Speaker 1: the other concern is is we don't even know if
- 6:30Speaker 1: those are authentic. So that's that's those are some of
- 6:34Speaker 1: the risks. The other risk contamination dosing errors. There's a
- 6:40Speaker 1: lot of instances where they'll be more or less of
- 6:43Speaker 1: the product in the vial than what's originally stated, and
- 6:48Speaker 1: so now you're you're dosing yourself inaccurately. You don't know
- 6:52Speaker 1: exactly what those dosages are, and you know, there's there's
- 6:57Speaker 1: significant risks as far as contamination bacteria. I've had some
- 7:04Speaker 1: some pretty had people call our office thinking we could
- 7:08Speaker 1: help them by having a you know, they injected some
- 7:13Speaker 1: some random random injectable peptide from online that they purchased
- 7:19Speaker 1: and at that point, go to the go to the
- 7:23Speaker 1: emergency room, or or you know, like find someone locally
- 7:27Speaker 1: to figure out maybe what contaminants there are going through
- 7:32Speaker 1: some detoxes. It's definitely critical. But you know, if you
- 7:36Speaker 1: actually look at the FDA Category two lists, there's nineteen
- 7:40Speaker 1: peptides that are currently under review. That includes your BPC
- 7:44Speaker 1: one five seven, c JC twelve ninety five. Right now
- 7:48Speaker 1: they're reviewing, they're they're stating there's insufficient safety and efficacy
- 7:53Speaker 1: data at a show. I believe there's been a significant
- 7:57Speaker 1: amount of pharmacies. There's been patients as well as clinicians
- 8:02Speaker 1: and practitioners that have reached out to the FDA saying, hey,
- 8:05Speaker 1: like we've seen these are some of the results in
- 8:09Speaker 1: the findings that we've found. When they first came out
- 8:12Speaker 1: with that ruling, I know, you know, we along with
- 8:17Speaker 1: a few of our colleagues and pharmacies had submitted letters
- 8:22Speaker 1: requesting that it doesn't need to be there. Being on
- 8:25Speaker 1: Category two doesn't necessarily mean it's unsafe. It just means
- 8:29Speaker 1: it's under evaluation. And just seeing you know what that's
- 8:36Speaker 1: done to the market. Now, there's just this huge increase
- 8:40Speaker 1: in these research use only haveptides what we're hoping to see,
- 8:45Speaker 1: and there's been some glimpses of it. You saw, like
- 8:49Speaker 1: RFK was on Joe Rogan's podcast a couple months ago
- 8:53Speaker 1: and was talking about how those those were classified illegally
- 8:58Speaker 1: and it was not not not adequate measures to put
- 9:04Speaker 1: those on that list just because there wasn't any risk
- 9:10Speaker 1: factors as far as the safety side of things. So
- 9:14Speaker 1: we're expecting at least some there's I think last week
- 9:19Speaker 1: we talked about like seven different specific peptides that we
- 9:24Speaker 1: expect to be back in the category one and what
- 9:27Speaker 1: that means just why that even matters to you guys,
- 9:31Speaker 1: and the research use only peptide side of things is
- 9:35Speaker 1: right now, you know, to have access to peptides, a
- 9:40Speaker 1: lot of them come through that research use only because
- 9:44Speaker 1: five O three BS the Category two list is like
- 9:48Speaker 1: cannot bulk compound or the FDA says like, don't don't
- 9:52Speaker 1: bulk compound bees, don't don't mass produce, And the FDA
- 9:57Speaker 1: regulates five O three BEE pharmacy versus five O three
- 10:01Speaker 1: A pharmacies are regulated by the state and the those pharmacies,
- 10:07Speaker 1: you know, they're not bulk compounding and they're not creating
- 10:10Speaker 1: thousands of aials in a single run and doing that
- 10:15Speaker 1: that large scale production or manufacturing, and so they're you know,
- 10:19Speaker 1: it's it's unique patient specific fials or peptides, and so
- 10:26Speaker 1: the pharmacy as well as the clinicians still has their
- 10:30Speaker 1: discretion of how they're going to utilize those and you know,
- 10:33Speaker 1: how how we utilize them as we see massive, massive
- 10:38Speaker 1: gains and the risks the benefits absolutely outweigh the risks
- 10:44Speaker 1: here from a health, longevity and performance standpoint, and so
- 10:51Speaker 1: you know what's so these some five O three a's
- 10:55Speaker 1: will will create and that's where we've been able to
- 10:59Speaker 1: still work with some great five three a's as well
- 11:02Speaker 1: as Angel's farm are. We we've been able to get
- 11:06Speaker 1: most all the peptides that we would want, and we're
- 11:10Speaker 1: confident in their their purity, their clutter, their efficacy, as
- 11:15Speaker 1: well as just h you know, the safety behind them
- 11:18Speaker 1: versus there's there's been so many cases, just a lot
- 11:23Speaker 1: of instances of you know, new new peptide shops on
- 11:28Speaker 1: the on the web and Internet of showing different ways
- 11:33Speaker 1: you can get peptides and then usually they'll they'll show
- 11:36Speaker 1: up fairly like low cost and what I've discovered there's
- 11:41Speaker 1: kind of two reasons for that. A lot of times
- 11:44Speaker 1: the amount of peptides that are in that vial is
- 11:48Speaker 1: a fraction of what you'd get from like a typical
- 11:52Speaker 1: compounded finished product or a peptide vial, or in other
- 11:57Speaker 1: cases it's just you know, you got to be careful
- 12:00Speaker 1: with what the product quality of that is, because you know,
- 12:04Speaker 1: it's not just you know, you get the peptide mix
- 12:08Speaker 1: and you put it in a vial and you kind
- 12:11Speaker 1: of ship it out. There's a whole process of sterilization
- 12:14Speaker 1: and cleaning and then verifying and making sure that it's
- 12:17Speaker 1: actually is what it is, and utilizing third party testing
- 12:23Speaker 1: as well as you know, batch segmenting and just making
- 12:27Speaker 1: sure that everything is really clean and safe and there's
- 12:31Speaker 1: no contaminants or no you know, leftover remnants of other
- 12:36Speaker 1: fragments or other peptides that are in there, and so
- 12:40Speaker 1: it's really critical to you know, be able to look
- 12:43Speaker 1: at that and so you know, the safe path, like
- 12:46Speaker 1: I was saying, would be through these five O three
- 12:48Speaker 1: A compounding pharmacies. They have to be prescribed through licensed providers.
- 12:53Speaker 1: You're getting pharmaceutical grade ingredients with verified purity that you know,
- 13:01Speaker 1: all the ingredients that go into that because you have
- 13:04Speaker 1: the peptide and then you also have there's different substrates
- 13:07Speaker 1: and things that like make that peptide usable to be
- 13:13Speaker 1: able to inject and not not burn or there's certain
- 13:18Speaker 1: instances where you know, it goes through a process obviously,
- 13:23Speaker 1: and so you want to be able to work with
- 13:27Speaker 1: a something there versus you know, if you look at
- 13:31Speaker 1: the r U O or the research use only versus
- 13:35Speaker 1: those medical grade peptides, you're u seeing research chemicals, there's
- 13:41Speaker 1: not really any oversight and you know, really unknown risks
- 13:48Speaker 1: or issues with those, and so it's it's you know,
- 13:51Speaker 1: that's that's probably the biggest thing. That other thing is
- 13:56Speaker 1: our goal with peptides is we want to extend health space,
- 14:00Speaker 1: not just live span, but those poor quality peptides can
- 14:05Speaker 1: create potential harm and so you know, the optimization should
- 14:10Speaker 1: not compromise safety, and so we we want to make
- 14:15Speaker 1: sure that you know, what what we're putting in our
- 14:18Speaker 1: body is is clean and pure and is not going
- 14:21Speaker 1: to create issues. Because what what we've seen with you know,
- 14:26Speaker 1: a lot of research use peptides, we'll see you know,
- 14:28Speaker 1: liver enzymes increase and those those are some things you
- 14:32Speaker 1: want to look like, watch and keep track of. Even
- 14:36Speaker 1: on the pures of peptides, there's certain certain ones that
- 14:41Speaker 1: we can see different markers be be improved or or change.
- 14:46Speaker 1: But specifically with toxicity from you know, some of these
- 14:51Speaker 1: r U O peptides, well we'll see those. Those are
- 14:54Speaker 1: some kind of early early warning signs for liver stress.
- 14:59Speaker 1: So you want to look at like alt as t
- 15:01Speaker 1: for your liver. You make sure you have some established
- 15:04Speaker 1: baselines before you jump in and just start peptides, get
- 15:08Speaker 1: some labs done and actually look at okay, this this
- 15:11Speaker 1: is where I am right now, And then with peptides,
- 15:14Speaker 1: what's that look like and what's moving and what's improving.
- 15:17Speaker 1: Maybe is there some things that aren't improving or getting
- 15:20Speaker 1: worse that that we need a monitor And that's where
- 15:23Speaker 1: we're working with really professionals that understand what they're doing
- 15:29Speaker 1: and can help guide you through that process. And so
- 15:31Speaker 1: that's really what we're working on. And like I said before,
- 15:37Speaker 1: you know, there is this regulatory turning point where you know,
- 15:41Speaker 1: the FDA is kind of like forced this this gray
- 15:45Speaker 1: market or black market of peptides. Now we're hoping July
- 15:49Speaker 1: is the next time they meet, and we're expecting a
- 15:53Speaker 1: big shift there to have there's at least seven key
- 15:57Speaker 1: peptides that we've heard of that should be getting back
- 16:00Speaker 1: on the category one list, which would make it a
- 16:04Speaker 1: lot easier for everyone to get access to because obviously
- 16:08Speaker 1: there's only so many five oh three A pharmacies that
- 16:12Speaker 1: you know. And then of those five oh three A,
- 16:15Speaker 1: who is confident and competent enough to actually make some
- 16:19Speaker 1: of these peptides as well, and so you'll start seeing
- 16:22Speaker 1: if these moved to the Cat one list, this would
- 16:26Speaker 1: be huge. So you have like BPC one five seven
- 16:30Speaker 1: amazing regenerative peptide, as well as TV five hundred motzi.
- 16:34Speaker 1: It's a mitochondrial peptide that's going to give you more energy,
- 16:38Speaker 1: more boost KPB phenomenal for immune and gut health. And
- 16:42Speaker 1: then CMAX brain cognitive function. You have ten two lane
- 16:47Speaker 1: of ten two is typically used for skin. It's it's
- 16:53Speaker 1: an immune intelligence peptide as well as you're going to
- 16:57Speaker 1: get a little more bronze. You can ten You get
- 17:00Speaker 1: out in the sun with bland and two and you
- 17:02Speaker 1: ten really well. And then pege m peg that's like
- 17:06Speaker 1: a kind of growth hormone releasing or a growth hormone
- 17:09Speaker 1: pathway peptide, and so you know, these they're they're widely
- 17:14Speaker 1: used on the regenerative and longevity medicine side of things,
- 17:18Speaker 1: and right now they're fairly limited. We we have some
- 17:22Speaker 1: different pharmacies that they're willing to make it, and some
- 17:26Speaker 1: amazing pharmacists that we work with. But you know, if
- 17:31Speaker 1: those move on to that Category one list or move
- 17:34Speaker 1: off the cat too, and I think we're going to
- 17:37Speaker 1: see a lot more access on really good, high quality peptides.
- 17:42Speaker 1: And and I think that's that's a good thing for
- 17:46Speaker 1: for the the world and the nation because you know,
- 17:51Speaker 1: if if you have a pharmacist that feels comfortable has
- 17:56Speaker 1: the regulatory backing to say yes, like I I'm I'm
- 18:01Speaker 1: gonna I can work with this and make more especially
- 18:05Speaker 1: the five O three b's will be able to mass produce,
- 18:08Speaker 1: not mass produced, but they'll be able to bulk supply
- 18:12Speaker 1: some of these other just game changing peptides. And so
- 18:16Speaker 1: really really looking forward to that. So just so you're
- 18:21Speaker 1: kind of aware Category one and so there's three different
- 18:25Speaker 1: categories that the FDA is kind of put these these
- 18:31Speaker 1: peptides on the roadmap. And like I said before, five
- 18:34Speaker 1: O three a's is they they have the liberty to
- 18:40Speaker 1: make whatever custom compounds they want versus five O three
- 18:44Speaker 1: bees all through a way. They're regulated heavily by the FDA.
- 18:49Speaker 1: But in a five O three A still all the
- 18:51Speaker 1: substances must meet FDA criteria in order to be used,
- 18:55Speaker 1: and so they have to go through a specific chain. Say,
- 18:59Speaker 1: if they're from outside the country, they have to go
- 19:01Speaker 1: through a specific chain. If they're coming from internally, it's
- 19:05Speaker 1: the same thing. They have to come through certified facilities
- 19:10Speaker 1: and also pass rigorous testing to make sure it's it's
- 19:15Speaker 1: safe and it is what it says it is. That's
- 19:18Speaker 1: the biggest risk factor. You can buy something online. You're
- 19:22Speaker 1: going to get a vial and I've even seen examples
- 19:26Speaker 1: where they don't label it at all, but on their
- 19:28Speaker 1: website maybe they'll say not for human use, but a
- 19:31Speaker 1: lot of times you'll get that vile say not for
- 19:34Speaker 1: human consumption, research use only and put that in your
- 19:40Speaker 1: body is probably not the smartest thing if your if
- 19:44Speaker 1: your goal is increasing health span, longevity and health and vibrance,
- 19:50Speaker 1: because you know, long term, if there's any sort of
- 19:53Speaker 1: toxicants in their long term use of those even short
- 19:58Speaker 1: term use could cause some serious damage. And so I
- 20:01Speaker 1: talked a little bit about those peptides, and you know,
- 20:06Speaker 1: just to give you a little bit of insight into
- 20:09Speaker 1: these seven peptides. You got BPC one five seven TB
- 20:13Speaker 1: five hundred months, c KPV, cimax, melanotan, peggy and these
- 20:20Speaker 1: are great and the common thread here they're derived from
- 20:27Speaker 1: or they mimic this natural human peptide peptide chains that
- 20:31Speaker 1: are in our body already. They're often fragments of endogenous
- 20:35Speaker 1: signaling molecules. So you get these better signaling pathways so
- 20:39Speaker 1: they can work within your existing biological pathways to kind
- 20:44Speaker 1: of tie right into the freeway and help with better communication.
- 20:49Speaker 1: If you think about like different pathways in the body,
- 20:52Speaker 1: it's like you can get a lot of traffic on
- 20:55Speaker 1: a highway and it's really tough to make your way
- 20:58Speaker 1: through versus you know, you get the right right peptide,
- 21:03Speaker 1: or you know that that wedge that just clears a
- 21:06Speaker 1: lane and gets things flowing and communicating better, you know,
- 21:10Speaker 1: And I think one I'll get into a little bit here,
- 21:15Speaker 1: but if you think about where the why peptides aren't
- 21:20Speaker 1: already they're they're gaining momentum and popularity like crazy. We've
- 21:25Speaker 1: already seen the GLP ones really give a huge boost
- 21:31Speaker 1: or just get a lot of popularity. And those are
- 21:34Speaker 1: big pharma produced. And the challenge that some of these,
- 21:40Speaker 1: a lot of these peptides have is they can they
- 21:43Speaker 1: can be used off label for so many different things
- 21:46Speaker 1: because they're so dynamic. It's not like you don't use
- 21:51Speaker 1: peptides just because you got a cold or you got
- 21:53Speaker 1: the flu, you're gonna use X or you know, it's
- 21:56Speaker 1: it's not like a drug where if you have condition
- 22:01Speaker 1: why you know, the answer is peptide X. That's that's
- 22:06Speaker 1: not necessarily how they work because they're they're dynamic, and
- 22:11Speaker 1: there's there's different uses. You know, one peptide can have
- 22:15Speaker 1: very many multiple uses. Where g LPs were great for
- 22:20Speaker 1: big pharmas you know, for weight loss, and so they
- 22:23Speaker 1: could patent it based on the condition of diabetes or
- 22:27Speaker 1: weight loss, and so they they market it under that
- 22:30Speaker 1: specific thing and that was there they could put a
- 22:34Speaker 1: patent on that versus you know once where these uh,
- 22:38Speaker 1: these peptides, one is it's it's a product of nature,
- 22:42Speaker 1: and then it's it's really difficult to commercialize that for
- 22:46Speaker 1: big pharma because there's not just like one specific condition
- 22:50Speaker 1: that it can can contrite or or do. And so
- 22:55Speaker 1: that's maybe that's a little bit behind, you know, the
- 22:59Speaker 1: the idea there, because if big pharma, you know, were
- 23:04Speaker 1: to try to take every one of these peptides and
- 23:07Speaker 1: patent it, you know, first of all, the cost of
- 23:10Speaker 1: getting those those drugs through trials is significantly high. As
- 23:16Speaker 1: well as, like I said before, as soon as it
- 23:19Speaker 1: goes through the trials, you know, for other you can
- 23:23Speaker 1: you can still utilize them for off label use and
- 23:27Speaker 1: other things. And it's there that's like natural base substances
- 23:34Speaker 1: that can you know, really like a pharmacy can replicate it.
- 23:38Speaker 1: And so the big pharma can't necessarily put a moat
- 23:43Speaker 1: around its drug and be able to maximize it because
- 23:47Speaker 1: everyone else is going to be able to kind of
- 23:49Speaker 1: make make similar things. And so hopefully that that gives
- 23:53Speaker 1: you an idea. One thing that we are seeing is
- 23:56Speaker 1: with red, a true tide that's a really popular peptide,
- 24:00Speaker 1: limited difficult to use. It's going through a lot of
- 24:03Speaker 1: the trials right now, but it sounds like that the
- 24:09Speaker 1: drug maker that's going through those trials is trying to
- 24:13Speaker 1: address every single possible condition that that peptide could treat,
- 24:19Speaker 1: and so they can do that, so the ability for
- 24:23Speaker 1: a compounding pharmacy to be able to make that custom
- 24:26Speaker 1: for a patient will be almost you know, zero, because
- 24:32Speaker 1: they'll have all these conditions that that drug will be
- 24:35Speaker 1: tied to and you know, potentially that will violate the
- 24:40Speaker 1: patent on that. So hopefully that gives you guys a
- 24:42Speaker 1: little bit of insight into kind of why big Pharma
- 24:46Speaker 1: isn't necessarily leading the charge on all the peptides because
- 24:50Speaker 1: and I think they have a lot to do with
- 24:52Speaker 1: them going on different lists because I think in the
- 24:56Speaker 1: future you're going to see more of these try to
- 24:59Speaker 1: go through different different drug pathways and things. And we
- 25:04Speaker 1: even have some we have some I rbs that we're
- 25:07Speaker 1: we're putting together for you know, our all of our
- 25:11Speaker 1: clients and patients to be part of you know, some
- 25:14Speaker 1: some you know, really good research on data as well
- 25:18Speaker 1: as uh, you know, we we want to be able
- 25:20Speaker 1: to publish that. Our goal is not necessarily make the
- 25:22Speaker 1: next blockbuster drug, but our goal is to provide access
- 25:26Speaker 1: to amazing medicine so you can live more more vibrant,
- 25:33Speaker 1: you know, more, more health resilience, resilient lives and have
- 25:39Speaker 1: better health span. So hopefully this was some some good
- 25:45Speaker 1: information for you, you know, just some key takeaways. Think
- 25:50Speaker 1: about it if you're going to probably be bombarded every
- 25:55Speaker 1: day and whether it's your social media feed, someone showing
- 25:59Speaker 1: you there's peptides all over the internet. There's all these
- 26:03Speaker 1: different research use only sites. Sometimes they won't even say
- 26:07Speaker 1: research use only, but make sure you're getting it through
- 26:11Speaker 1: a five O three a license, compounding, pharmacy, or somewhere
- 26:16Speaker 1: where it's actually there's there's a pharmacist or someone with
- 26:20Speaker 1: a license that it's actually like putting their name on
- 26:24Speaker 1: the line to say, hey, this is safe, effective, I've
- 26:27Speaker 1: done research on this, I've used this. You know, those
- 26:31Speaker 1: are some key things that that we really pay attention to.
- 26:36Speaker 1: And it's not just some you know a lot of
- 26:38Speaker 1: there's white labeled options out there with different peptides that
- 26:43Speaker 1: just don't really know where the safety or the efficacy.
- 26:47Speaker 1: So find it from a really really valuable source. And
- 26:51Speaker 1: this is where you know those five O three as.
- 26:54Speaker 1: I think I'll have a ton of value for that
- 26:57Speaker 1: for the mass public. Work with a provider to make
- 27:02Speaker 1: sure you're watching your lab, seeing where things are moving
- 27:06Speaker 1: and going, and really paying attention to that. So thanks
- 27:09Speaker 1: for joining us. We'll see you next time on Ageless
- 27:13Speaker 1: Future podcast. Have an amazing day, everybody,